Which two acts are commonly associated with pediatric labeling and safety communication updates?

• A. PLLR and PREA
• B. FDC Act and FFDCA
• C. HIPAA and MSA
• D. PREA and BPCA

Answer: (D)

Pediatric drug labeling and safety communications are driven by laws that specifically push for pediatric data and reward sponsors to generate it. The Pediatric Research Equity Act requires FDA to seek out pediatric studies when a drug is being developed or labeled for adults, so information about safety and dosing in children ends up in the labeling. The Best Pharmaceuticals for Children Act provides incentives, like a six-month extension of market exclusivity, to sponsors to conduct pediatric studies, which also expands the pediatric data that can appear in labeling and informs safety communications for pediatric use. Together, these acts are the ones most closely associated with ensuring pediatric-specific labeling and related safety information. The other options don’t target pediatric labeling and safety updates in the same way.